---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-002744"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2023-03-03T23:59:59+00:00"
generated_at: "2026-06-18T13:01:21.755808+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Kala enrolls first patient in PCED trial, closes $31M private placement

## Summary
- Enrolled first patient in CHASE Phase 2b trial of KPI-012 for persistent corneal epithelial defect; top-line data targeted for Q1 2024.
- Closed $31.0M private placement in December 2022, extending cash runway into Q1 2025.
- Completed sale of EYSUVIS and INVELTYS to Alcon in Q3 2022 to focus on rare eye diseases.
- Reported Q4 and FY2022 financial results; specific figures not available in the provided excerpt.

## SEC filing metadata
- accession: 0001558370-23-002744
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2023-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000155837023002744/0001558370-23-002744-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000155837023002744/kala-20230303x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-002744
- JSON: https://secwatch.observer/filing/0001558370-23-002744.json
- Plain text: https://secwatch.observer/filing/0001558370-23-002744.txt

## Key facts
- Earnings Releases
  KALA BIO, Inc. reported financial results for the quarter and year ended December 31, 2022.
  - Period: the quarter and year ended December 31, 2022
  - Result: reported results
  source text: On March 3, 2023, Kala Pharmaceuticals, Inc. announced its financial results for the quarter and year ended December 31, 2022 and provided a general business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479419/000155837023002744/0001558370-23-002744-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.